Capital One National Association’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital One National Association’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$973K	Sell	7,838 -321	-4%	-$37.5K	0.07%	228
2018 Q1	$909K	Sell	8,159 -332	-4%	-$39.7K	0.06%	238
2017 Q4	$1.01M	Sell	8,491 -1,143	-12%	-$139K	0.07%	230
2017 Q3	$1.35M	Buy	9,634 +2,664	+38%	+$362K	0.09%	188
2017 Q2	$848K	Buy	6,970 +3,676	+112%	+$428K	0.06%	252
2017 Q1	$399K	Buy	3,294 +175	+6%	+$22.6K	0.03%	376
2016 Q4	$381K	Buy	3,119 +867	+38%	+$106K	0.03%	381
2016 Q3	$276K	Buy	2,252 +158	+8%	+$20.3K	0.02%	434
2016 Q2	$245K	Sell	2,094 -1,040	-33%	-$148K	0.02%	453
2016 Q1	$436K	Sell	3,134 -180	-5%	-$26.4K	0.04%	360
2015 Q4	$633K	Sell	3,314 -436	-12%	-$76.2K	0.05%	296
2015 Q3	$587K	Buy	3,750 +93	+3%	+$17K	0.06%	306
2015 Q2	$661K	Sell	3,657 -11,252	-75%	-$1.94M	0.06%	301
2015 Q1	$2.58M	Buy	14,909 +1,276	+9%	+$231K	0.23%	102
2014 Q4	$2.52M	Buy	13,633 +212	+2%	+$39.3K	0.24%	109
2014 Q3	$2.23M	Sell	13,421 -556	-4%	-$91.3K	0.22%	122
2014 Q2	$2.18M	Buy	13,977 +9	+0.1%	+$1.42K	0.2%	130
2014 Q1	$2.13M	Buy	13,968 +385	+3%	+$61.2K	0.21%	125
2013 Q4	$1.8M	Sell	13,583 -1,425	-9%	-$171K	0.17%	158
2013 Q3	$1.74M	Sell	15,008 -309	-2%	-$33.9K	0.18%	162
2013 Q2	$1.41M	Buy	+15,317	New	+$1.48M	0.15%	171

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital One National Association's ALXN Position: Q2 2018 in Review

Capital One National Association reduced its Alexion Pharmaceuticals (ALXN) stake by 3.9% in Q2 2018, selling an estimated $37.5K and leaving 7,838 shares worth $973K. The position accounts for 0.07% of the portfolio, ranked #228.

Capital One National Association first reported a position in ALXN in Q2 2013 and has held it in 21 quarters since. The position peaked at $2.58M in Q1 2015. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Capital One National Association held 7,838 shares of Alexion Pharmaceuticals worth $973K as of Q2 2018.
Capital One National Association sold 321 Alexion Pharmaceuticals shares in Q2 2018, an estimated $37.5K.
Alexion Pharmaceuticals made up 0.07% of Capital One National Association's portfolio in Q2 2018, its #228 holding.
Capital One National Association first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 21 quarters since.
Capital One National Association's Alexion Pharmaceuticals position peaked at $2.58M in Q1 2015.
601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Capital One National Association's 13F filing for Q2 2018, filed 16 Jul 2018.